MOTS-c

Published · Researched 2026-09-21

Slug: mots-c · Category: Metabolic & Weight Loss · Researched: 2026-09-20

1. Overview

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a 16-amino-acid peptide encoded by a short open reading frame within the mitochondrial 12S rRNA gene — making it, uniquely among research peptides, a product of mitochondrial DNA rather than nuclear DNA. It was discovered by Dr. Pinchas Cohen's laboratory at the University of Southern California (USC) Leonard Davis School of Gerontology, with the discovery paper by Lee et al. published in Cell Metabolism in March 2015 ("The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance," Lee C, Zeng J, Drew BG, et al., Cell Metab. 2015;21(3):443–454).

Purpose: Metabolic regulation and exercise-mimetic signaling. Under metabolic stress, MOTS-c translocates from mitochondria to the cell nucleus, regulating gene expression via the antioxidant response element (ARE)/NFE2L2 pathway. Its primary metabolic cascade runs through the folate–methionine cycle: MOTS-c inhibits the folate cycle, causing accumulation of the intermediate AICAR (5-aminoimidazole-4-carboxamide ribonucleotide), a potent AMPK activator. AMPK activation then promotes glucose uptake, fatty acid oxidation, and mitochondrial biogenesis. In mice, MOTS-c prevented age-dependent and high-fat-diet-induced insulin resistance, reduced obesity, and enhanced skeletal muscle glucose uptake through AMPK-dependent mechanisms. The "exercise mimetic" framing comes from its activation of many of the same metabolic pathways triggered by physical exercise.

Current 2026 version — CB4211: CB4211, a stabilized analog of MOTS-c developed by CohBar (founded by Dr. Cohen), entered a Phase 1a/1b clinical trial in July 2018 for NASH and obesity. Phase 1a completed (November 2019), with CohBar announcing Phase 1b initiation in obese subjects with NAFLD (20 subjects, 4-week double-blind placebo-controlled evaluation, endpoints including MRI-PDFF liver fat, body weight, NASH/obesity biomarkers). The trial was temporarily suspended in late 2018 for persistent mild injection-site reactions and later delayed by COVID-19 pandemic impact at clinical sites. CB4211 post-2020 status: UNVERIFIED — no published Phase 1b results or further CB4211 clinical activity found in this research; the program appears stalled with no current active trials identified. As of September 2026, plain MOTS-c is sold only as an unapproved research chemical; there is no approved pharmaceutical version.

2. Social Standing

Platform pulse (Threads / Facebook Groups / Instagram):

• Threads — moderate chatter. A verified account (@spencer.johnsons, Aug 2026) framed MOTS-c as the only peptide encoded by mitochondrial DNA, describing its translocation-to-nucleus AMPK retrograde loop and claiming WADA banned it (the WADA ban is also reported elsewhere with a 2024 date — see UNVERIFIED log). An ordinary user (@dill28will, May 2026) posted anxiously about their first MOTS-c injection, drew 9 replies, and later followed up that it was "a non-event" and that they were "still kicking" two months later — a small, informal reassurance thread rather than a results report.
• Facebook Groups — weak. No dedicated MOTS-c groups were found. Searching all public groups returned no MOTS-c-specific groups (only small generic peptide groups). A query for MOTS-c posts in the ~10,000-member group "Biohacking, Longevity, CRISPR, Supplements, Life Extension, Wim Hof" returned zero results. MOTS-c has effectively no footprint in the highest-signal layer for this project.
• Instagram — weak. No Instagram owner content for MOTS-c was identified in this research. Activity was found on adjacent platforms instead: TikTok explainer posts (e.g., @VitalityHubTT, @dr_soko covering MOTS-c's AMPK/thermogenesis mechanisms with hundreds of likes), a YouTube FAQ video ("MOTS-C: Mitochondrial Peptide for Metabolic Reset, Muscle Preservation & Longevity Upgrade," ~2025), and the rapamycin.news longevity forum, where users discussed injecting MOTS-c (one user in Feb 2026 described a 10mg injection as stinging but said they went out and mowed the lawn right after) and debating IM vs. subQ administration.

Group consensus: There is no organized group consensus — the discussion is fragmented across peptide blogs, TikTok explainers, and wellness telemedicine PR. The dominant framing is "exercise mimetic / longevity crossover": the peptide is discussed as much in aging forums (rapamycin.news) as in fat-loss circles, with users positioning it as complementary to GLP-1s (mitochondrial efficiency + muscle preservation during weight cutting) rather than an appetite suppressant.

Viral moments: No single viral moment identified. Two notable attention waves: (a) July 2026, when an FDA advisory committee was reported (by vendor-affiliated and Men's Health/Yahoo coverage) to be reviewing seven peptides including MOTS-c for possible inclusion on the 503A compounding bulks list; (b) a June 2026 wellness-clinic press push branding it "wellness' hottest trend," which is sponsored content (marked as such).

Praise (anecdotal, unverifiable): Anecdotal reports credit it with smoother endurance training, cleaner energy within days, better glucose control, reduced post-exercise soreness, and — in one widely repeated Reddit-origin anecdote — a swimmer posting a personal record distance after their first dose. Biohacking books (Ben Greenfield's Boundless) recommend 10mg weekly before endurance exercise.

Complaints / skepticism:

• Oral bioavailability skepticism is the dominant complaint. Some vendors market oral or capsule MOTS-c products; community voices (e.g., the brainflow.co FAQ, Reddit-derived discussion) argue a 16-amino-acid peptide taken orally would be digested, not absorbed intact — injected subQ is the only administration the community takes seriously. This is echoed as caution, not proof.
• Instability after reconstitution is another recurring concern: one widely cited Reddit-derived claim is that reconstituted MOTS-c degrades very fast (~50% at 2 hours, ~90% at 3 hours) — UNVERIFIED, single-user claim, widely repeated.
• Injection sting/pain reported casually by users (rapamycin.news, Feb 2026).
• CB4211's persistent mild injection-site reactions (per CohBar's own disclosures, 2018) are cited as evidence that the molecule itself may be irritating to inject.

Verified quotes (paraphrased; attributed by platform + context):

• Threads (@dill28will, May 2026, first-injection post): user asked for reassurance about their first MOTS-c shot; months later reported it was uneventful and they were fine — a reassurance thread, not a results claim.
• Threads (@spencer.johnsons, verified, Aug 2026): claimed MOTS-c is the only mtDNA-encoded peptide and that WADA banned it in 2026 — WADA ban year conflicts with 2024 reported elsewhere; UNVERIFIED.
• Threads commenter (@grateful_rn) summarized a widely cited line: MOTS-c is not FDA-approved, available only for research or via compounding pharmacies — consistent with regulatory facts.
• Threads comment (sponsored/vendor): a reply on the MOTS-c thread promoted "Amino Club" with a 20%-off affiliate discount code — flagged as sponsored.
• rapamycin.news user (Feb 2026): injected 10mg, found the injection painful, went out and mowed the lawn afterward; asked the community about dosing rationale.
• muscleandbrawn.com summarizing Reddit users: one reported a 10mg 3×-weekly / then 10mg weekly protocol and called it a great adjunct for mitochondrial dysfunction while noting they personally saw little effect as a heavy exerciser; another reported swimming a personal record distance after their first dose while also training hard on other protocols — attributing causation is impossible.

3. Social validation — Tier 3 (weak)

Tier: Tier 3 — weak (single primary platform: Threads).

Adjacent-platform activity (not counted toward the primary-layer tier): TikTok explainers (@VitalityHubTT, @dr_soko, hundreds of likes), a YouTube MOTS-c FAQ (Hq_h5ZmZviY), the rapamycin.news forum thread ("Does anyone try MOTS-c?", active Feb 2026), peptide-blog ecosystem (jaycampbell.com, muscleandbrawn.com, brainflow.co, exploring-peptides.com), and press/PR (Yahoo/Men's Health via y.gogonow.de, July 2026; California Trim Clinic press release, June 2026 — sponsored).

Assessment: MOTS-c is a known molecule with published human-adjacent trial data (CB4211), but the social evidence base for it is thin — far weaker than flagship peptides. It qualifies for inclusion on research merit (two mitochondrial-derived peptides exist in this category: humanin and MOTS-c), but its community pulse is a quiet hum, not a wave.

4. Key Specs

Known safety signals in humans: Essentially none beyond mild injection-site reactions (CB4211 trial) and transient mild nausea/redness reported anecdotally by community users. No controlled human safety data for plain MOTS-c exists — stated plainly.

5. Pricing (all prices observed 2026-09-20)

No brand MSRP exists — MOTS-c is not a branded pharmaceutical; it is sold by research-chemical vendors at unregulated street pricing.

Street price range (US, 10 mg vials): $40–$60 per 10 mg vial; 40 mg bulk vials $110–$132 bring cost down to $2.75–$3.30/mg. A typical community cycle (5–10 mg, 2–3×/week) consumes roughly 1–3 vials/month → **$60–$180/month** at street pricing.

Observed Marketplace used range: none seen — no Facebook Marketplace listings for MOTS-c identified in this research.

6. What Is Included / What Else Is Needed

Typically included with a vendor order: Lyophilized MOTS-c vial (10 mg or 40 mg) in sealed vial, with claimed COA (batch-dependent). Some vendors bundle reconstitution instructions; syringe kits are usually sold separately.

What else is needed (per community protocols):

• Bacteriostatic water for reconstitution (vendors specify e.g. 2 mL per 10 mg vial)
• U-100 insulin syringes (subQ administration; units-per-dose depends on reconstitution — e.g., 10 mg vial + 2 mL → 100 units = 5 mg)
• Alcohol swabs
• Refrigeration (2–8 °C after reconstitution; unopened vials stored cool/dark; −20 °C for long-term)

7. Support Reality

• Core Research Peptides: advertises one-business-day email support; damaged/wrong items replaced with order number + photo, no formal RMA process — vendor-stated, not independently confirmed by community reports in this research.
• Peptide Partners: order cancellations allowed before shipment (full refund); shipped orders non-refundable; damage/incorrect goods require packaging photos emailed within 48 hours of delivery — vendor-stated.
• General: No MOTS-c vendor warranty/return program is brand-backed; all purchases are "research use only" sales with limited consumer protection. No community complaint threads about MOTS-c vendors surfaced in this research; vendor reputation evidence is thin.
• The affiliate/sponsored layer is present: Threads comments contain vendor affiliate codes (e.g., "SHOP20"), and price blogs carry vendor discount codes (marked sponsored).

8. Community Verdict

MOTS-c is the most scientifically interesting peptide in this category — real mechanism (mtDNA-encoded, folate–AICAR–AMPK axis), real Phase 1 human data via its CB4211 analog — but its community footprint is thin: no Facebook Group presence and only sparse Threads discussion, with the loudest current voices being TikTok explainers and vendor-affiliated blogs. Users who try it describe it as an energy/endurance adjunct rather than a weight-loss drug, and the dominant community caution is that oral products are almost certainly a waste of money. It reads as a longevity-crossover niche item, not a mainstream fat-loss pick.

9. Regulatory & Safety Status (plain language)

• NOT approved by the FDA or EMA for any use. It is sold as a "research chemical, not for human use" — meaning vendors disclaim it, no dosing information is regulated, and purity is vendor-claimed (third-party COAs are voluntary).
• Reported (not independently confirmed) regulatory developments: multiple 2026 sources claim MOTS-c came off the FDA's Category 2 list in April 2026 and that an FDA advisory committee voted 7–5 in July 2026 to recommend it for the 503A compounding bulks list — a non-binding recommendation. UNVERIFIED: I could not confirm these against an FDA docket in this research; the claims originate from vendor-affiliated sources and one Yahoo/Men's Health piece.
• WADA: reported as banned under S4.4 (AMPK activators); sources disagree on the year (2024 vs 2026) — UNVERIFIED exact year. Competitive tested athletes should treat it as prohibited.
• Human safety data: essentially none for plain MOTS-c. The CB4211 trial showed no serious adverse events but persistent mild injection-site reactions. Community anecdotes mention mild nausea and injection sting. No known organ toxicity has been reported — and no systematic study has looked for it. This is a research chemical with an unquantified human risk profile.
• Telemedicine/wellness clinics (e.g., RxForPeptides.com via California Trim Clinic PR, June 2026 — sponsored) advertise prescription peptide therapy, but MOTS-c's compounding availability under 503A/503B remains legally uncertain.

10. Missing-Image Views + UNVERIFIED Points Log

Photos (6 of 8 views captured, 2026-09-20): all are vendor product photos — the only real photography layer that exists for MOTS-c; each is a distinct vendor's own product image, visually verified and converted to JPEG. No AI-generated or synthetic images used.

Missing views (honest gaps): mots-c-owner-in-use.jpg (no real owner/use photos exist anywhere found) and mots-c-scale.jpg (no scale-reference photos found). Vendor renders do not show vials beside a scale object.

UNVERIFIED points (marking, not asserting):

1. Human half-life of MOTS-c — no published data found; community compensates with 2–3× weekly dosing on assumption of short half-life.
2. Post-reconstitution degradation rate (50% at 2h / 90% at 3h) — single Reddit-derived claim, widely repeated, no primary source.
3. CB4211 Phase 1b results (ALT/AST/glucose/liver-fat readouts) — from a 2025 Medium retrospective citing no primary publication; not confirmed.
4. CB4211 program status after ~2020 — no current trials or company updates found; appears stalled.
5. WADA ban year (2024 vs 2026 claims conflict).
6. FDA advisory-committee 7–5 vote (July 2026) and April 2026 Category 2 removal — reported by vendor-affiliated sources; no FDA docket confirmation in this research.
7. All vendor purity claims (99–99.9%), third-party testing claims, and COAs — vendor-stated, not independently verified.
8. Oral/sublingual MOTS-c bioavailability — community opinion says negligible; no comparative human data either way.
9. Anecdotal results claims (endurance PRs, glucose improvements, energy boosts) — unverifiable self-reports.
10. Facebook Marketplace pricing — no listings observed; no used-market data exists in this research.

Not medical advice. This is research material only; consult a qualified clinician.

Named sources

• Threads @spencer.johnsons — **Threads — moderate chatter.** A verified account (@spencer.johnsons, Aug 2026) framed MOTS-c as the only peptide encoded by mitochondrial DNA, describing its translocation-to-nucleus AMPK retrograde loop and claiming WADA banned it (the WADA ban is also… (Aug 2026)
• @dill28will — An ordinary user (@dill28will, May 2026) posted anxiously about their first MOTS-c injection, drew 9 replies, and later followed up that it was "a non-event" and that they were "still kicking" two months later — a small, informal reassurance thread rather… (May 2026)
• TikTok @VitalityHubTT — Activity was found on adjacent platforms instead: TikTok explainer posts (e.g., @VitalityHubTT, @dr_soko covering MOTS-c's AMPK/thermogenesis mechanisms with hundreds of likes), a YouTube FAQ video ("MOTS-C: Mitochondrial Peptide for Metabolic Reset, Muscle…
• TikTok @dr_soko — Activity was found on adjacent platforms instead: TikTok explainer posts (e.g., @VitalityHubTT, @dr_soko covering MOTS-c's AMPK/thermogenesis mechanisms with hundreds of likes), a YouTube FAQ video ("MOTS-C: Mitochondrial Peptide for Metabolic Reset, Muscle…
• Threads @grateful_rn — Threads commenter (@grateful_rn) summarized a widely cited line: MOTS-c is not FDA-approved, available only for research or via compounding pharmacies — consistent with regulatory facts.
• y.gogonow.de — *Adjacent-platform activity (not counted toward the primary-layer tier):** TikTok explainers (@VitalityHubTT, @dr_soko, hundreds of likes), a YouTube MOTS-c FAQ (Hq_h5ZmZviY), the rapamycin.news forum thread ("Does anyone try MOTS-c?", active Feb 2026),… (Feb 2026)
• brainflow.co — Everest Peptides (via brainflow.co price reporting) | 10 mg / 40 mg | **$39.99** (10 mg), **$109.99** (40 mg) ≈ $2.75/mg at 40 mg | Cheapest per-mg option found; code BRAINFLOW reportedly takes another 10% (affiliate — **sponsored**) | | Peptide Partners…
• CB4211 — *Assessment:** MOTS-c is a known molecule with published human-adjacent trial data (CB4211), but the *social* evidence base for it is thin — far weaker than flagship peptides.
• CohBar — - CB4211's persistent mild injection-site reactions (per CohBar's own disclosures, 2018) are cited as evidence that the molecule itself may be irritating to inject. (2018)
• California — - Telemedicine/wellness clinics (e.g., RxForPeptides.com via California Trim Clinic PR, June 2026 — **sponsored**) advertise prescription peptide therapy, but MOTS-c's compounding… (June 2026)

Source URLs were not recorded for these references.